Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Calcitriol (injectable dosage form)

November 27, 2018

Non-proprietary name

Calcitriol (injectable dosage form)

Safety measure

Precautions should be revised in the package insert.

The following language should be added to the Clinically Significant Adverse Reactions subsection of the Adverse Reactions section (revised language is underlined):

Shock, anaphylaxis:

Shock or anaphylaxis may occur. Patients should be carefully monitored. If any abnormalities such as decreased blood pressure, dyspnea, or flushing are observed, administration of this drug should be discontinued and appropriate measures should be taken.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3·3·2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>